During a visit to the French Ministry of Health, Emilie Sam explained to me the mechanisms for French investments in the innovation of new biomedical technologies. Many of the new life-saving products have a big impact on their budget for medicines in France. It will be interesting to wait and see at what rate this growth continues.
“In 2016, 54.3% (~€65 million) of the Uncovered Innovative Procedures List allowance correspond to innovative genetic procedures which can be split into ~€36 million for oncogenetic procedures and ~€29 million for constitutional genetic procedures.”
Check out Emilie Sam’s full poster for more details.
